Table 4 Comparison of patients with HBsAg loss at EOT and in Group 1

Gender, male (%)

5 (83.3%)

12 (70.6%)

Age (years)

24.8 ± 2.7

26.5 ± 5.7

Baseline ALT (U/L)

249.8 ± 214.0

133.6 ± 130.1

Baseline HBV DNA (log₁₀IU/mL)

4.3 ± 1.5

5.8 ± 2.1

Baseline HBsAg (log₁₀IU/mL)

2.6 ± 0.9

2.9 ± 0.6

On-treatment HBsAg decline at week 24 (log₁₀IU/mL)

1.6 ± 1.4

1.2 ± 0.8

On-treatment HBV DNA decline at week 24 (log₁₀IU/mL)

1.9 ± 1.6

3.7 ± 1.6

Duration of IFN (months)

17.3 ± 4.9

14.5 ± 5.2